Possible mechanism of dexamethasone therapy for prostate cancer: Suppression of circulating level of interleukin‐6
暂无分享,去创建一个
Tatsuo Igarashi | Tomohiko Ichikawa | Takeshi Ueda | K. Akakura | T. Igarashi | T. Ichikawa | Hiroyoshi Suzuki | Akira Komiya | Hiroyoshi Suzuki | T. Ueda | Haruo Ito | Haruo Ito | Koichiro Akakura | A. Komiya
[1] H. Klocker,et al. Immunohistochemical localization of interleukin‐6 and its receptor in benign, premalignant and malignant prostate tissue , 2000, The Journal of pathology.
[2] Y. Horiguchi,et al. Serum interleukin 6 as a prognostic factor in patients with prostate cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[3] T. Nishiyama,et al. Hormone/Antihormone Withdrawal and Dexamethasone for Hormone‐Refractory Prostate Cancer , 1998, International journal of urology : official journal of the Japanese Urological Association.
[4] K. Akakura,et al. Androgen receptor content of prostate carcinoma cells estimated by immunohistochemistry is related to prognosis of patients with stage D2 prostate carcinoma , 1996, Cancer.
[5] Y. Furuya,et al. Incidence and Characteristics of Antiandrogen Withdrawal Syndrome in Prostate Cancer after Treatment with Chlormadinone Acetate , 1998, European Urology.
[6] D. Tweardy,et al. Interleukin‐6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway , 2000, The Prostate.
[7] J. Simons,et al. Characterization of the role of IL‐6 in the progression of prostate cancer , 1999, The Prostate.
[8] N Nonomura,et al. Potential mechanism for the effects of dexamethasone on growth of androgen-independent prostate cancer. , 2001, Journal of the National Cancer Institute.
[9] H. Scher,et al. Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] T. Miki,et al. Low doses of oral dexamethasone for hormone‐refractory prostate carcinoma , 2000, Cancer.
[11] G. Murphy,et al. Circulating levels of interleukin‐6 in patients with hormone refractory prostate cancer , 1999, The Prostate.
[12] H. Klocker,et al. Interleukin-6 regulates prostate-specific protein expression in prostate carcinoma cells by activation of the androgen receptor. , 1998, Cancer research.
[13] W. Farrar,et al. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. , 2000, Cancer research.
[14] N. Bruchovsky,et al. Activation of the Androgen Receptor N-terminal Domain by Interleukin-6 via MAPK and STAT3 Signal Transduction Pathways* , 2002, The Journal of Biological Chemistry.
[15] J. Buckner,et al. Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone‐refractory metastatic prostate carcinoma , 1995, Cancer.
[16] R. Oyasu,et al. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. , 1997, Cancer research.
[17] H. Scher,et al. Hormone-refractory (D3) prostate cancer: refining the concept. , 1995, Urology.